Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A phase I dose-escalation and metabolomics study of metformin combined with chemotherapy and/or immunotherapy in solid malignancies

    Cancer Categories
    • Breast,Gastrointestinal (GI),Gynecologic,Lung,Skin
    Karmanos Trial ID
    • 2024-050
    NCT ID
    • NCT07098299
    Age Group
    • Adult
    Scope
    • Local
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator

    Objective:

    Primary Objectives:

    • Evaluate the dose limiting toxicities (DLTs) of metformin alone and in combination with chemotherapy and/or immunotherapy (IO) in patients with solid malignancies
    • Determine the maximum tolerated dose (MTD) of metformin in combination with chemotherapy and/or IO in patients with solid malignancies

    Secondary Objective:

    • Assess efficacy parameters
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions